Browse
Submit Data
Databases
API
Help

Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

15 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcription profiling of human breast cancer patients sensitive to docetaxel

ABSTRACT: These patients were sensitive to docetaxel treatment, exhibiting less than 25% residual tumor.

ORGANISM(S): Homo sapiens

SUBMITTER: Eric Wooten

PROVIDER: E-GEOD-350 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Publications

Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer.

Chang Jenny C JC Wooten Eric C EC Tsimelzon Anna A Hilsenbeck Susan G SG Gutierrez M Carolina MC Elledge Richard R Mohsin Syed S Osborne C Kent CK Chamness Gary C GC Allred D Craig DC O'Connell Peter P

Lancet (London, England) 20030801 9381

<h4>Background</h4>Systemic chemotherapy for operable breast cancer substantially decreases the risk of death. Patients often have de novo resistance or incomplete response to docetaxel, one of the most active agents in this disease. We postulated that gene expression profiles of the primary breast cancer can predict the response to docetaxel.<h4>Methods</h4>We took core biopsy samples from primary breast tumours in 24 patients before treatment and then assessed tumour response to neoadjuvant do ...[more]

PMID: 12907009

Similar Datasets

Transcription profiling of human breast tumors resistant or sensitive to docetaxel treatment

Project description:This SuperSeries is composed of the following subset Series: GSE349: These patients proved resistant to docetaxel treatment, exhibiting residual tumor of 25% or greater remaining volume. Resistant GSE350 These patients were sensitive to docetaxel treatment, exhibiting less than 25% residual tumor.

2007-10-26 | E-GEOD-6434 | biostudies-arrayexpress

Sensitive

Project description:These patients were sensitive to docetaxel treatment, exhibiting less than 25% residual tumor. Keywords: repeat sample

2003-06-26 | GSE350 | GEO

Transcription profiling of human sensitive and resistant tumours identify gene expression patterns in primary breast-cancer specimens that might predict response to taxanes.

Project description:These patients proved resistant to docetaxel treatment, exhibiting residual tumor of 25% or greater remaining volume.

2007-10-04 | E-GEOD-349 | biostudies-arrayexpress

Resistant

Project description:These patients proved resistant to docetaxel treatment, exhibiting residual tumor of 25% or greater remaining volume. Keywords: repeat sample

2003-06-26 | GSE349 | GEO

Transcriptomic profiling of triple-negative breast cancer (TNBC) patient-derived xenografts (PDX) sensitive and resistant to docetaxel.

Project description:SurePrint G3 Human Gene Expression Microarray v2 was used to obtain gene expression profiles of two different TNBC PDX models sensitive to docetaxel and in the docetaxel resistant TNBC PDX models derived from both initially sensitive.

2019-07-30 | GSE110153 | GEO

Epigenetic profiling of docetaxel resistance in Breast Cancer

Project description:Illumina Infinium MethylationEPIC Beadchip was used to obtain DNA methylation profiles across 850000 CpGsites in nine different breast cancer PDX models. Docetaxel resistant and residual disease PDX models were also analyzed

2019-07-18 | GSE110184 | GEO

Gene expression data of sensitive, Docetaxel resistant and Paclitaxel resistant MDA-MB-231 Cells

Project description:The taxanes, namely Paclitaxel and Docetaxel, are important and widely used cancer chemotherapy drugs in the treatment of invasive and metastatic human breast cancer. Although treatment with the taxanes is beneficial to many patients, drug-responsive tumors in patients with metastatic breast cancer often display resistance to these drugs, either initially or over time following the continued administration of chemotherapy drugs. To investigate the patterns of cross-resistance with the taxane drugs and to identify potential mechanisms of resistance, we generated a series of MDA-MB-231 taxane resistant cell lines. We then used microarrays to determine gene expression differences between sensitive, Docetaxel and Paclitaxel resistant MDA-MB-231 cells. RNA isolated from three independent passages of sensitive, Docetaxel and Paclitaxel resistant cell lines and purified using the Qiagen RNeasy Mini Kit. Total RNA was processed and hybridized to Affymetrix Genechip HU133A arrays.

2011-04-22 | E-GEOD-28784 | biostudies-arrayexpress

Expression data from prostate cancer cell lines C4-2B (docetaxel sensitive) and TaxR (docetaxel resistant) cells

2013-08-01 | GSE47040 | GEO

Expression data from prostate cancer cell lines C4-2B (docetaxel sensitive) and TaxR (docetaxel resistant) cells

Project description:Prostate cancer C4-2B cells were cultured in docetaxel in a dose-escalation manner. After nine months selection, cells were able to divide freely in 5 nM docetaxel, with a specific sets of genes been deregulated. We performed global gene expression analysis by cDNA microarrays to identify genes responsible for docetaxel resistance in TaxR cells. Docetaxel resistant TaxR cells were selected from C4-2B cells during long time docetaxel treatment. Genes responsible for docetaxel resistance were identified using C4-2B vs. TaxR RNA extraction and hybridization on Affymetrix microarrays.

2013-08-01 | E-GEOD-47040 | biostudies-arrayexpress

Gene expression profiles of pretreatment biopsies from dose-dense-docetaxel-treated breast cancers

Project description:The purpose of this study was to identify molecular markers of pathologic response to neoadjuvant dose-dense docetaxel treatment using gene expression profiling on pretreatment biopsies. Patients with high-risk, operable breast cancer were treated with 75 mg/m2 IV of docetaxel on day 1 of each cycle every 2 weeks x 4 cycles . Tumor tissue from pretreatment biopsies was obtained from 12 patients enrolled in the study. Gene expression profiling were done on serial sections of the biopsies from patients that achieved a pathologic complete response (pCR) and compared to those with residual disease, non-pCR (NR).

2011-04-22 | GSE28796 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data